FDA approves Cyberonics' VNS (vagus nerve stimulation) anxiety trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Cyberonics the go-ahead to begin a pilot study to investigate the use of its implantable NCP vagus nerve stimulation (VNS) device as a treatment for three of five types of anxiety disorders - obsessive-compulsive disorder, panic disorder and adult onset post-traumatic stress disorder. The device, which was approved by the agency for the treatment of epilepsy in 1997, will be assessed in up to 30 patients at four sites, says the Houston, Texas company.